Insulet Corporation $PODD Shares Bought by AlphaQuest LLC

AlphaQuest LLC raised its position in shares of Insulet Corporation (NASDAQ:PODD) by 211.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,858 shares of the medical instruments supplier’s stock after acquiring an additional 2,618 shares during the period. AlphaQuest LLC’s holdings in Insulet were worth $1,191,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of PODD. True Wealth Design LLC raised its stake in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the period. Golden State Wealth Management LLC grew its position in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in Insulet during the 2nd quarter worth $35,000. Whittier Trust Co. of Nevada Inc. grew its stake in Insulet by 48.9% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares in the last quarter. Finally, Quent Capital LLC acquired a new position in shares of Insulet in the 3rd quarter worth approximately $49,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PODD. Canaccord Genuity Group raised their target price on shares of Insulet from $432.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price objective for the company. in a report on Monday, January 26th. Stifel Nicolaus initiated coverage on Insulet in a research note on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price objective on the stock. Barclays lifted their price objective on shares of Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Royal Bank Of Canada boosted their target price on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Twenty investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $375.05.

Insulet Stock Up 0.3%

Shares of Insulet stock opened at $255.81 on Monday. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The stock has a 50 day moving average price of $291.55 and a two-hundred day moving average price of $309.27. The stock has a market capitalization of $18.00 billion, a P/E ratio of 74.15, a PEG ratio of 1.42 and a beta of 1.41. Insulet Corporation has a 12-month low of $230.05 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.08 EPS. Equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.